121 related articles for article (PubMed ID: 33149212)
1. Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients.
Stanojković TP; Matić IZ; Petrović N; Stanković V; Kopčalić K; Besu I; Đorđić Crnogorac M; Mališić E; Mirjačić-Martinović K; Vuletić A; Bukumirić Z; Žižak Ž; Veldwijk M; Herskind C; Nikitović M
Sci Rep; 2020 Nov; 10(1):19002. PubMed ID: 33149212
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional Inflammatory Signature in Healthy Donors and Different Radiotherapy Cancer Patients.
O'Brien G; Kamuda M; Cruz-Garcia L; Polozova M; Tichy A; Markova M; Sirak I; Zahradnicek O; Widłak P; Ponge L; Polanska J; Badie C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256152
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the main PSA glycoforms in aggressive prostate cancer.
Gratacós-Mulleras A; Duran A; Asadi Shehni A; Ferrer-Batallé M; Ramírez M; Comet J; de Llorens R; Saldova R; Llop E; Peracaula R
Sci Rep; 2020 Nov; 10(1):18974. PubMed ID: 33149259
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer.
Stone BV; Laviana AA; Luckenbaugh AN; Huang LC; Zhao Z; Koyama T; Conwill R; Hoffman K; Joyce DD; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
J Urol; 2021 Mar; 205(3):761-768. PubMed ID: 33252300
[TBL] [Abstract][Full Text] [Related]
5. Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments.
Fossati N; Giannarini G; Joniau S; Sedelaar M; Sooriakumaran P; Spahn M; Rouprêt M;
Eur Urol Oncol; 2022 Oct; 5(5):587-600. PubMed ID: 33249083
[TBL] [Abstract][Full Text] [Related]
6. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.
Krajewski W; Moschini M; Chorbińska J; Nowak Ł; Poletajew S; Tukiendorf A; Afferi L; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Cianflone F; Mari A; Di Trapani E; Hendricksen K; Alvarez-Maestro M; Rodríguez-Serrano A; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Ploussard G; Laukhtina E; Tully K; Kołodziej A; Krajewska J; Piszczek R; Xylinas E; Zdrojowy R;
World J Urol; 2021 Jul; 39(7):2545-2552. PubMed ID: 33230571
[TBL] [Abstract][Full Text] [Related]
7. Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma?
Roussel E; Peeters E; Vanthoor J; Bozzini G; Muneer A; Ayres B; Sri D; Watkin N; Bhattar R; Parnham A; Sangar V; Lau M; Joice G; Bivalacqua TJ; Chipollini J; Spiess PE; Hatzichristodoulou G; de Vries L; Brouwer O; Albersen M;
BJU Int; 2021 May; 127(5):606-613. PubMed ID: 33180969
[TBL] [Abstract][Full Text] [Related]
8. A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.
Massi MC; Gasperoni F; Ieva F; Paganoni AM; Zunino P; Manzoni A; Franco NR; Veldeman L; Ost P; Fonteyne V; Talbot CJ; Rattay T; Webb A; Symonds PR; Johnson K; Lambrecht M; Haustermans K; De Meerleer G; de Ruysscher D; Vanneste B; Van Limbergen E; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Avuzzi B; Giandini T; Valdagni R; Cicchetti A; Azria D; Jacquet MF; Rosenstein BS; Stock RG; Collado K; Vega A; Aguado-Barrera ME; Calvo P; Dunning AM; Fachal L; Kerns SL; Payne D; Chang-Claude J; Seibold P; West CML; Rancati T
Front Oncol; 2020; 10():541281. PubMed ID: 33178576
[No Abstract] [Full Text] [Related]
9. Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study.
Wang H; Mendez LC; Morton G; Loblaw A; Mesci A; Chung HT; Chan S; Huang X; Downes MR; Vesprini D; Liu SK
Radiother Oncol; 2021 Feb; 155():80-85. PubMed ID: 33172830
[TBL] [Abstract][Full Text] [Related]
10. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; van der Kwast TH; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; van der Poel HG; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Cornford P
Eur Urol; 2021 Feb; 79(2):243-262. PubMed ID: 33172724
[TBL] [Abstract][Full Text] [Related]
11. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis.
von Eyben FE; Bauman G; von Eyben R; Rahbar K; Soydal C; Haug AR; Virgolini I; Kulkarni H; Baum R; Paganelli G
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260535
[TBL] [Abstract][Full Text] [Related]
12. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
13. MRI Characteristics Accurately Predict Biochemical Recurrence after Radical Prostatectomy.
Manceau C; Beauval JB; Lesourd M; Almeras C; Aziza R; Gautier JR; Loison G; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M; Ploussard G
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33256176
[TBL] [Abstract][Full Text] [Related]
14. Oncologic Outcomes of Salvage Chemotherapy in Patients with Recurrent or Metastatic Lesions after Radical Nephroureterectomy: A Multi-Institutional Retrospective Study.
Ikeda M; Matsumoto K; Hirayama T; Koguchi D; Murakami Y; Matsuda D; Okuno N; Utsunomiya T; Taoka Y; Irie A; Iwamura M
Chemotherapy; 2020; 65(5-6):134-140. PubMed ID: 33254168
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
[TBL] [Abstract][Full Text] [Related]
16. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Sawutz D; Philipson R; Coll R; Narayan VM; Treasure FP; Yla-Herttuala S; Parker NR; Dinney CPN
Lancet Oncol; 2021 Jan; 22(1):107-117. PubMed ID: 33253641
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway.
Jarvis P; Ho A; Sundram F
Nucl Med Commun; 2021 Mar; 42(3):332-336. PubMed ID: 33252512
[TBL] [Abstract][Full Text] [Related]
18. Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of
Belli ML; Sarnelli A; Mezzenga E; Cesarini F; Caroli P; Di Iorio V; Strigari L; Cremonesi M; Romeo A; Nicolini S; Matteucci F; Severi S; Paganelli G
Front Oncol; 2020; 10():531660. PubMed ID: 33251129
[TBL] [Abstract][Full Text] [Related]
19. Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer.
Heninger E; Sethakorn N; Kosoff D; Hematti P; Kuczler MD; Pienta KJ; Lang JM
Oncotarget; 2020 Nov; 11(46):4253-4265. PubMed ID: 33245727
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
